IN THE CLAIMS:

Claims 1-4, 6, 8-10, 12, 15-23, 25-30, 32, 33, 35-37, 39, 42, 43, 46 and 47 are currently pending in the application. Claims 1, 8, 27, 46 and 47 have been amended herein. Claims 6, 12, 15-23, 25, 26, 33, 35-37, 39, 42, and 43 are canceled herein. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (Currently Amended) A method for producing mRNA encoding a *Plasmodium falciparum* apical membrane antigen-1 (AMA-1) ectodomain, or a functional part thereof, in a yeast cell, said method comprising:

providing said yeast cell with a nucleic acid encoding said ectodomain or functional part thereof, wherein the functional part thereof comprises the amino acid sequence corresponding to amino acids residues selected from the group consisting of ~~parts spanning from amino acid residue~~ 25-442, 97-318, 97-442, and 97-545 of SEQ ID NO: 6, wherein the encoding nucleic acid comprises a nucleotide sequence of FIG. 1 encoding the ectodomain or the functional part thereof, and wherein at least one glycosylation site is removed from said *Plasmodium falciparum* AMA-1 ectodomain, and wherein said nucleic acid is modified to utilize said yeast cell's codon usage, and wherein said *Plasmodium falciparum* AMA-1 ectodomain or the functional part thereof exhibits specificity for mAb 4G2.

2. (Previously Presented) The method according to claim 1, further comprising expressing said nucleic acid in said yeast cell.

3. (Previously Presented) The method according to claim 2, further comprising purifying said *Plasmodium* AMA-1 ectodomain or functional part thereof.

4. (Previously presented) The method according to claim 1, wherein at least one putative yeast polyadenylation consensus sequence in the nucleic acid has been modified.

5- 7 (Cancelled).

8. (Currently amended) The method according to ~~claim 6~~claim 1, wherein the mRNA encoding *Plasmodium falciparum* AMA-1 ectodomain comprises mRNA encoding *Plasmodium falciparum* Vietnam-Oak Knoll strain ectodomain.

9. (Previously Presented) The method according to claim 1, wherein said yeast cell is *Pichia.*

10. (Previously Presented) The method according to claim 9, wherein said yeast cell is *Pichia pastoris.*

11-26. (Canceled).

27. (Currently Amended) A process for producing a *Plasmodium falciparum* apical membrane antigen-1 (AMA-1) ectodomain or a functional part thereof, said method comprising:

providing a yeast cell with an isolated or recombinant nucleic acid encoding *Plasmodium falciparum* AMA-1 ectodomain or a functional part thereof, wherein the functional part thereof comprises the amino acid sequence corresponding to amino acids residues selected from the group consisting of ~~parts spanning from amino acid residue~~ 25-442, 97-318, 97-442, and 97-545 of SEQ ID NO: 6 wherein the encoding nucleic acid comprises a nucleotide sequence encoding the ectodomain or the functional part thereof of FIG. 1, and wherein at least one glycosylation site is removed from said *Plasmodium falciparum* AMA-1 ectodomain, and wherein said nucleic acid is modified to utilize a yeast cell's codon usage, and wherein said *Plasmodium falciparum* AMA-1 ectodomain or the functional part thereof exhibits specificity for mAb 4G2; and

collecting formed *Plasmodium falciparum* AMA-1 ectodomain or functional part ~~thereof~~thereof.

28. (Previously Presented) The process of claim 27, further comprising purifying said formed *Plasmodium* AMA-1 ectodomain or functional part thereof.

29. (Previously Presented) The process of claim 27, wherein said yeast cell is *Pichia.*

30. (Previously Presented) The process of claim 29, wherein said yeast cell is *Pichia pastoris.*

31-45 (Canceled).

46. (Currently amended) A method for producing mRNA encoding a functional part of a *Plasmodium falciparum* apical membrane antigen-1 (AMA-1) ectodomain in a yeast cell, said method comprising:

providing said yeast cell with a nucleic acid encoding said functional part of said ectodomain, wherein the functional part thereof comprises the amino acid sequence corresponding to amino acids residues selected from the group consisting of ~~parts spanning from amino acid residue~~ 25-442, 97-318, 97-442, and 97-545 of SEQ ID NO: 6, wherein the encoding nucleic acid comprises ~~the~~ a nucleotide sequence encoding the functional part thereof of FIG. 1, and wherein at least one glycosylation site is removed from said *Plasmodium falciparum* AMA-1 ectodomain, and wherein said nucleic acid is modified to utilize said yeast cell's codon usage, and wherein said *Plasmodium ~~falciaparum~~ falciparum* AMA-1 ectodomain or the functional part thereof exhibits specificity for mAB4G2.

47. (Currently amended) A method for producing a functional part of a *Plasmodium ~~falciaparum~~ falciparum* apical membrane antigen-1 (AMA-1) ectodomain, said method comprising:

providing said yeast cell with an isolated or recombinant nucleic acid encoding a functional part of a *Plasmodium ~~falciaparum~~ falciparum* AMA-1 ectodomain, wherein the functional part thereof comprises the amino acid sequence corresponding to amino acids residues selected from the group consisting of ~~parts spanning from amino acid residue~~ 25-442, 97-318, 97-442, and 97-545 of SEQ ID NO: 6, wherein the encoding nucleic acid comprises ~~the~~ a nucleotide sequence

encoding the functional part thereof of FIG. 1, and wherein at least one glycosylation site is removed from said *Plasmodium falciparum* AMA-1 ectodomain, and wherein said nucleic acid is modified to utilize said yeast cell's codon usage, and wherein said *Plasmodium* ~~*falciaparum*~~ *falciparum* AMA-1 ectodomain or the functional part thereof exhibits specificity for mAB4G2; and

collecting the formed functional part of *Plasmodium* ~~*falciaparum*~~ *falciparum* AMA-1.